Guess Who Picked Up Axovant Sciences Ltd. (NYSE:AXON) Shares

0
22
Thermometer Temperature Influenza Flu Fever

 

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Axovant Sciences Ltd. (NYSE:AXON) reported that Viking Global has picked up 75,000,000 of common stock as of 2017-06-14.

The acquisition brings the aggregate amount owned by Viking Global to a total of 75,000,000 representing a 69.8% stake in the company.

For those not familiar with the company, Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company is focused to develop its lead product candidate, intepirdine, a selective 5-hydroxytryptamine 6 receptor antagonist, for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. The Company’s pipeline also includes RVT-103 and RVT-104.

A glance at Axovant Sciences Ltd. (NYSE:AXON)’s key stats reveals a current market capitalization of $2.56 Billion based on $107.39 Million shares outstanding and a price at last close of $23.31 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-04-17, Vernon picked up 53,937 at a purchase price of $18.54. This brings their total holding to 53,937 as of the date of the filing.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an Axovant Sciences Ltd. (NYSE:AXON) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.